No Prescription |
 |
 | ||
|
SALOFALK GR Asacol |
|
| ||
No Prescription » Prescription Drugs 14 » SALOFALK GR Asacol Mesalamine is used to treat ulcerative colitis (a condition in which part or all of the lining of the colon [large intestine] is swollen or worn away). Mesalamine delayed-release tablets and controlled-release capsules may be used to treat ulcerative colitis that affects any part of the colon. Mesalamine suppositories and enemas should only be used to treat inflammation of the lower part of the colon. Mesalamine is in a class of medications called anti-inflammatory agents. It works by stopping the body from producing a certain substance that may cause pain or inflammation.Mesalamine comes as a delayed-release tablet and a controlled-release capsule to take by mouth and as a suppository and an enema to use in the rectum. The delayed-release tablet is usually taken three times a day and the controlled-release capsule is usually taken four times a day. The suppository is usually used one to three times a day and the enema is usually used once a day at bedtime. Follow the directions on your prescription label carefully and ask your doctor or pharmacist to explain any part you do not understand. Take or use mesalamine exactly as directed. Do not take or use more or less of it or take or use it more often than prescribed by your doctor.Swallow the tablets whole; do not split chew or crush them. Be careful not to break the protective coating on the tablets.If you are unable to swallow the capsules you may mix the contents of the capsules with water. Open a capsule and sprinkle all of the beads it contains in a small glass of water. Stir the beads into the water and drink the mixture right away. Do not store mixtures of beads and water for later use.The enema and suppositories are for rectal use only.You should begin to feel better during the first few days or weeks of your treatment with mesalamine. Continue to take or use mesalamine until you finish your prescription even if you feel better at the beginning of your treatment. Do not stop taking or using mesalamine without talking to your doctor.Mesalamine suppositories and enemas may stain clothing flooring fabric and other surfaces. Take precautions to prevent staining when you use these medications. Buy SALOFALK GR Asacol and other Prescription Drugs 14 products online at Medstore. 551
About SALOFALK GR Asacol: Product Type: Prescription Drugs 14 SALOFALK GR ( Asacol Pentasa Rowasa Canasa Generic Mesalamine ) SALOFALK GR (Asacol Pentasa Rowasa Canasa Generic Mesalamine) Asacol Pentasa Rowasa Canasa Generic Mesalamine 250mg Tabs 30 (3 x 10) Asacol Pentasa Rowasa Canasa Generic Mesalamine SALOFALK GR
View more Prescription Drugs 14 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
